Administered With A Pde5i For The Treatment Of Erectile Dysfunction

Palatin Technologies

20/06/2024 13:23

June 20 (Reuters) - Palatin Technologies Inc  PTN.A :
    * PALATIN ANNOUNCES THE INITIATION OF A PHASE 2 CLINICAL
STUDY OF
BREMELANOTIDE CO-ADMINISTERED WITH A PDE5I FOR THE TREATMENT OF
ERECTILE DYSFUNCTION (ED)
    * PALATIN TECHNOLOGIES: POTENTIAL PHASE 3 CLINICAL STUDY IN
ED
PATIENTS WHO DO NOT RESPOND TO PDE5I MONOTHERAPY TO START IN H1
2025

Source text for Eikon:  ID:nPn1YnLwca 
Further company coverage:  PTN.A 

 ((Reuters.Briefs@thomsonreuters.com;))